Präzisionsonkologie und molekulare Tumorboards – Konzepte, Chancen und Herausforderungen
| العنوان: | Präzisionsonkologie und molekulare Tumorboards – Konzepte, Chancen und Herausforderungen |
|---|---|
| المؤلفون: | Klaus H. Metzeler, Julian Walter Holch, Andreas Jung, Christoph B. Westphalen, Volker Heinemann, Wolfgang Hiddemann |
| المصدر: | TumorDiagnostik & Therapie. 39:124-132 |
| بيانات النشر: | Georg Thieme Verlag KG, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | 0301 basic medicine, Pathology, medicine.medical_specialty, Standard of care, medicine.diagnostic_test, business.industry, Personalized treatment, MEDLINE, General Medicine, Precision medicine, Clinical trial, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Oncology, Precision oncology, 030220 oncology & carcinogenesis, Medicine, Treatment strategy, Tumor board, Medical physics, Routine clinical practice, business, Genetic testing |
| الوصف: | Die immer umfassendere molekulare Charakterisierung von Tumoren ermoglicht eine „Prazisionsonkologie“ mit besonders effektiven und nebenwirkungsarmen Therapien. „Targeted Therapies“ erzielen bei bestimmten Tumorentitaten grose Erfolge. Jedoch bestehen Schwierigkeiten in der praktischen Umsetzung und Nutzenbewertung zunehmend individualisierter Behandlungsansatze. Recent developments in genomics allow a more and more comprehensive genetic analysis of human malignancies, and have sparked hopes that this will contribute to the development of novel targeted, effective and well-tolerated therapies. While targeted therapies have improved the prognosis of many cancer patients with certain tumor types, “precision oncology” also brings along new challenges. Highly personalized treatment strategies require new strategies for clinical trials and translation into routine clinical practice. We review the current technical approaches for “universal genetic testing” in cancer, and potential pitfalls in the interpretation of such data. We then provide an overview of the available evidence supporting treatment strategies based on extended genetic analysis. Based on the available data, we conclude that “precision oncology” approaches that go beyond the current standard of care should be pursued within the framework of an interdisciplinary “molecular tumor board”, and preferably within clinical trials. |
| تدمد: | 1439-1279 0722-219X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d0cafcd939fd00b40bddb398d5cba79Test https://doi.org/10.1055/s-0044-100825Test |
| رقم الانضمام: | edsair.doi.dedup.....5d0cafcd939fd00b40bddb398d5cba79 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14391279 0722219X |
|---|